Recursion Pharmaceuticals Inc (NASDAQ: RXRX) kicked off on Monday, down -5.59% from the previous trading day, before settling in for the closing price of $6.98. Over the past 52 weeks, RXRX has traded in a range of $4.97-$15.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 132.77%. While this was happening, its average annual earnings per share was recorded 1.11%. With a float of $222.94 million, this company’s outstanding shares have now reached $226.26 million.
Recursion Pharmaceuticals Inc (RXRX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Recursion Pharmaceuticals Inc is 22.57%, while institutional ownership is 75.67%. The most recent insider transaction that took place on Sep 26 ’24, was worth 42,005. In this transaction President and COO of this company sold 6,000 shares at a rate of $7.00, taking the stock ownership to the 521,138 shares. Before that another transaction happened on Sep 26 ’24, when Company’s Officer proposed sale 6,000 for $7.00, making the entire transaction worth $42,005.
Recursion Pharmaceuticals Inc (RXRX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 1.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Take a look at Recursion Pharmaceuticals Inc’s (RXRX) current performance indicators. Last quarter, stock had a quick ratio of 6.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 38.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.72 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Looking closely at Recursion Pharmaceuticals Inc (NASDAQ: RXRX), its last 5-days average volume was 4.33 million, which is a drop from its year-to-date volume of 5.87 million. As of the previous 9 days, the stock’s Stochastic %D was 56.82%. Additionally, its Average True Range was 0.40.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 14.75%, which indicates a significant decrease from 34.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.00% in the past 14 days, which was lower than the 74.74% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.02, while its 200-day Moving Average is $9.03. However, in the short run, Recursion Pharmaceuticals Inc’s stock first resistance to watch stands at $6.93. Second resistance stands at $7.26. The third major resistance level sits at $7.43. If the price goes on to break the first support level at $6.42, it is likely to go to the next support level at $6.25. Now, if the price goes above the second support level, the third support stands at $5.92.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
The company with the Market Capitalisation of 1.90 billion has total of 237,664K Shares Outstanding. Its annual sales at the moment are 44,580 K in contrast with the sum of -328,070 K annual income. Company’s last quarter sales were recorded 14,420 K and last quarter income was -97,540 K.
